USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$1.41B
Market Cap
-
P/E Ratio
-3.03
EPS
$38.28
52 Week High
$9.98
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $490M |
| Total Revenue | $940M |
| Cost Of Revenue | $451M |
| Costof Goods And Services Sold | $451M |
| Operating Income | -$99M |
| Selling General And Administrative | $390M |
| Research And Development | $199M |
| Operating Expenses | $589M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $18M |
| Interest Expense | $7.4M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $158K |
| Income Before Tax | -$92M |
| Income Tax Expense | $4.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$96M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$99M |
| Ebitda | -$99M |
| Net Income | -$96M |
| Field | Value (USD) |
|---|---|
| Total Assets | $968M |
| Total Current Assets | $724M |
| Cash And Cash Equivalents At Carrying Value | $69M |
| Cash And Short Term Investments | $69M |
| Inventory | $150M |
| Current Net Receivables | $115M |
| Total Non Current Assets | $243M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $925K |
| Intangible Assets Excluding Goodwill | $925K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $75M |
| Short Term Investments | $369M |
| Other Current Assets | $22M |
| Other Non Current Assets | - |
| Total Liabilities | $705M |
| Total Current Liabilities | $247M |
| Current Accounts Payable | $45M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $59M |
| Total Non Current Liabilities | $458M |
| Capital Lease Obligations | $125M |
| Long Term Debt | $308M |
| Current Long Term Debt | $41M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $474M |
| Other Current Liabilities | $132M |
| Other Non Current Liabilities | $32M |
| Total Shareholder Equity | $263M |
| Treasury Stock | - |
| Retained Earnings | -$1B |
| Common Stock | $66K |
| Common Stock Shares Outstanding | $65M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $24M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $17M |
| Capital Expenditures | $19M |
| Change In Receivables | - |
| Change In Inventory | $5.8M |
| Profit Loss | - |
| Cashflow From Investment | -$23M |
| Cashflow From Financing | $8.4M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$30M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$96M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $490M |
| Total Revenue | $940M |
| Cost Of Revenue | $451M |
| Costof Goods And Services Sold | $451M |
| Operating Income | -$99M |
| Selling General And Administrative | $390M |
| Research And Development | $199M |
| Operating Expenses | $589M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $18M |
| Interest Expense | $7.4M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $158K |
| Income Before Tax | -$92M |
| Income Tax Expense | $4.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$96M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$99M |
| Ebitda | -$99M |
| Net Income | -$96M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Tandem Diabetes Care, Inc. is a leading medical device manufacturer based in San Diego, California, focused on revolutionary insulin delivery technologies for individuals with insulin-dependent diabetes. The company's flagship product, the t:slim X2 insulin delivery system, is distinguished by its integration of advanced features, including automated insulin delivery and continuous glucose monitoring, positioning Tandem at the forefront of diabetes management. With a steadfast commitment to innovation and patient-centric solutions, Tandem is poised to leverage its strong R&D framework to capture growth opportunities in the evolving diabetes care market, addressing the rising demand for personalized and intelligent healthcare technologies.